Last week, the Nasdaq Composite and the S&P 500 declined 0.14% and 0.13%, respectively. The Dow Jones Industrial Average gained 0.34% in the same period. Investor sentiment is still hung upon President...
Last week, J&J JNJ announced plans to invest more than $55 billion over the next four years to expand its manufacturing footprint in the United States as the Trump administration considers imposing tariffs...
J&J JNJ announced plans to invest more than $55 billion in the United States over the next four years to boost manufacturing, R&D and technology in the country. This represents a 25% increase in investment compared...
The consistency in their dividend payments makes them dependable stocks in a volatile market.
Earlier this month, the company appointed three new directors, including Starboard Value CEO Jeffrey Smith, to its board as part of an agreement with the activist hedge fund after months of back-and-forth....
U.S. stocks shook off a weak start and ended slightly higher, enough to break a four-week losing streak
This week, the FDA approved J&J’s JNJ Tremfya for its second inflammatory bowel disease (“IBD”) condition, Crohn’s disease (“CD”), and Novartis’ NVS Fabhalta for its third indication, C3...
Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel disease (IBD) condition — moderately to severely active Crohn’s disease...
Johnson & Johnson says it will invest more than $55 billion within the United States over the next four years, including four new manufacturing plants
Pfizer PFE has sold off its remaining stake in consumer health company Haleon HLN to institutional investors and Haleon itself for around $3.3 billion. Pfizer sold its 7.3% stake in Haleon, or approximately...